FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action
This article was originally published in The Tan Sheet
Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run
You may also be interested in...
Dr. Reddy’s launches Allegra-D equivalent
Expert advisors to FDA encourage firms to develop new OTC cough suppressants to replace dextromethorphan, which some argue is ineffective and poses an abuse risk
Members of an FDA panel tipped their hats to the Consumer Healthcare Product Association's efforts to reduce dextromethorphan abuse, but floated enhancements to the program